REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Peptide Library

AICAR

Acadesine / AICA Ribonucleotide / ZMP

Longevity & Anti-Aging

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide, also known as Acadesine) is a synthetic analog of adenosine monophosphate that directly activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. Originally developed as a cardioprotective agent for use during cardiac surgery, it gained notoriety as an "exercise mimetic" capable of triggering metabolic adaptations typically associated with endurance training. AICAR is banned by the World Anti-Doping Agency (WADA) and is classified as a metabolic modulator on the prohibited substances list.

Mechanism of Action

AMP-kinase activator that mimics the metabolic effects of exercise. Increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through direct AMPK phosphorylation. Shifts cellular metabolism toward an endurance-trained state.

Research Protocols

For research purposes only. Not medical advice.

Research protocols use 150-500mg daily via subcutaneous injection. Animal studies used 500mg/kg. Often cycled 4-8 weeks. Sometimes combined with GW501516 in research settings.

Research Notes

Clinical Research Status

AICAR underwent Phase III clinical trials for reduction of ischemic injury during coronary artery bypass graft surgery, though it ultimately did not receive FDA approval for this indication. Research interest shifted dramatically after 2008 Salk Institute studies demonstrated that AICAR administration alone could improve running endurance in sedentary mice by 44%. It remains an investigational compound with no approved medical indications, though academic research into AMPK activation continues across metabolic disease, cancer, and aging fields.

Key Published Findings

The landmark Narkar et al. (2008) paper in Cell demonstrated that AICAR treatment for 4 weeks reprogrammed muscle metabolism toward oxidative fiber types and enhanced running endurance without exercise training. AMPK activation by AICAR increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through PGC-1alpha signaling pathways. In cardiac ischemia studies, AICAR reduced post-surgical complications including atrial fibrillation and the need for inotropic support.

Safety Profile

Clinical trial data from cardiac surgery studies showed AICAR to be relatively well-tolerated at therapeutic doses, with hypoglycemia and lactic acidosis being the primary dose-limiting concerns. Renal toxicity has been observed at higher doses due to uric acid accumulation from purine metabolism. Long-term safety data in healthy populations is essentially nonexistent, as most human data comes from short-term perioperative use in cardiac patients.

Comparison to Related Compounds

Unlike GW501516 (Cardarine), which activates PPAR-delta downstream of AMPK, AICAR directly activates AMPK itself, affecting a broader range of metabolic pathways including autophagy and mTOR suppression. SLU-PP-332 represents a newer generation of exercise mimetics targeting estrogen-related receptors rather than AMPK. Metformin also activates AMPK but through indirect mitochondrial complex I inhibition rather than direct allosteric activation, resulting in a different pharmacological profile.

Community Observations

Users report enhanced endurance and fat oxidation, though the effects are considered modest compared to expectations set by animal studies. The high cost per effective dose and requirement for injection limit its practical use in performance enhancement contexts. Some users combine AICAR with GW501516 based on the original Salk Institute research showing synergistic effects, though this combination carries compounded safety unknowns.

Half-Life

~2-3 hours

Reconstitution

Bacteriostatic water (BAC) or sterile saline

Storage

Lyophilized

Refrigerate 2-8C up to 12 months.

Reconstituted

Refrigerate 2-8C. Use within 14 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

AcadesineAICA RibonucleotideZMP

PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer